Vantage logo

Macrogenics scoops its Asco bounce

A tiny glimpse at very early data has more than tripled Macrogenics’ market cap. The pressure is now on to confirm these signals.

Vantage logo

Reality bites for Macrogenics 

Hopes are fading for margetuximab in breast cancer, which looks unlikely to show an overall survival benefit in the Sophia study.